Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults.
In a randomized, double-blinded study, 77 elderly seropositive volunteers were immunized with either liposome-adjuvanted or control subvirion vaccine containing 15 micrograms/dose of haemagglutinin from influenza A/Taiwan/1/86 (H1N1) virus. The liposome vaccine was well-tolerated but elicited serologic responses that were no different in frequency or magnitude from those induced by the control vaccine. Less than 20% of subjects in either group mounted a 4-fold or greater rise in antibody titer. Peripheral blood anti-influenza A cytotoxic T lymphocyte activity was enhanced to a greater extent by the liposome vaccine than by the control subvirion vaccine. It remains unclear whether liposome-adjuvanted formulations would have an advantage over conventional influenza vaccines for routine annual reimmunization of targeted high-risk populations.
Powers
D C
DC
Glennan Center for Geriatries and Gerontology, Eastern Virginia Medical School, Norfolk 23507, USA.
D000276:Adjuvants, Immunologic; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D003602:Cytotoxicity, Immunologic; D004311:Double-Blind Method; D004337:Drug Carriers; D004797:Enzyme-Linked Immunosorbent Assay; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control; D008081:Liposomes; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D004337:Drug Carriers; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D008081:Liposomes